IP Library Granted Patent US 9,283,388
Granted Patent B2
US 9,283,388 · App. 13/831,381 · Granted Mar 15, 2016

Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods

Inventors: James R. Thacker (Homer, AK); Konstantinos Alataris (Belmont, CA); Bradford Evan Gliner (Sammamish, WA)
Assignee: Nevro Corporation
A61N1/36071A61N1/0551A61N1/0558A61N1/36075A61N1/36171A61N1/36185
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,283,388
App. No.
13/831,381
Granted
Mar 15, 2016
Kind
B2
Abstract

Selective high-frequency spinal chord modulation for inhibiting pain with reduced side affects and associated systems and methods are disclosed. In particular embodiments, high-frequency modulation in the range of from about 1.5 KHz to about 100 KHz may be applied to the patient's spinal cord region to address pelvic pain without creating paresthesia in the patient.

Claims (38)

1. A method of treating a pelvic pain indication, exclusive of pelvic pain associated with total body pain, comprising:

configuring a signal generator to generate and deliver a pelvic pain therapy signal to a target location, wherein the target location is between T12-L5, inclusive, via one or more implanted signal delivery devices coupled to the signal generator,

wherein at least a portion of the therapy signal is at a frequency in a frequency range of from 1.5 kHz to 100 kHz, includes pulses with a pulse width in a pulse width range of 10 microseconds to 333 microseconds, and has an amplitude in an amplitude range of 0.1 mA to 20 mA, which at least partially alleviates the pelvic pain indication, exclusive of pelvic pain associated with total body pain, without generating paresthesia.

2. The method of claim 1 , wherein the pelvic pain is selected from the group consisting of: osteitis pubis pain, cancer pain, gluteus maximus pain, visceral pain, piriformis pain, ischiogluteal pain, levator ani pain, and coccydynia pain.

3. The method of claim 1 , wherein the frequency range is from 3 kHz to 20 kHz.

4. The method of claim 1 , wherein the frequency range is from 5 kHz to 15 kHz.

5. The method of claim 1 , wherein the one or more signal delivery devices include a percutaneous lead having one or more electrodes disposed toward a distal end of the percutaneous lead.

6. The method of claim 1 , wherein the pulse width is between 30 microseconds and 35 microseconds.

7. The method of claim 1 , wherein the pulse width is between 25 microseconds and 166 microseconds.

8. The method of claim 1 wherein the frequency is 10 kHz.

9. A method of treating a non-total body pain pelvic pain indication, comprising:

applying an electrical therapy signal to a target vertebral location at a patient's spinal cord, wherein the target vertebral location is between T12-L5, inclusive, wherein at least a portion of the electrical therapy signal (a) is at a frequency in a frequency range of from 1.5 kHz to 100 kHz, (b) has pulses in a pulse width range of 10 microseconds to 333 microseconds, and (c) is at an amplitude in an amplitude range of 0.1 mA to 20 mA, and wherein the electrical therapy signal treats the pelvic pain indication without generating paresthesia in the patient.

10. The method of claim 9 , wherein the pelvic pain indication is selected from the group consisting of: osteitis pubis pain, cancer pain, gluteus maximus pain, visceral pain, piriformis pain, ischiogluteal pain, levator ani pain, and coccydynia pain.

11. The method of claim 9 , wherein the frequency range is from 3 kHz to 20 kHz.

12. The method of claim 9 , wherein the frequency range is from 5 kHz to 15 kHz.

13. The method of claim 9 , further comprising programming the signal generator to generate the electrical therapy signal.

14. The method of claim 9 ,

wherein the electrical therapy signal is delivered via one or more implanted signal delivery devices coupled to an implanted signal generator, wherein the signal generator is programmed with instructions that, when executed, treat the pelvic pain indication by generating and delivering the electrical therapy signal to the target vertebral location.

15. The method of claim 14 , wherein the one or more signal delivery devices include a percutaneous lead having one or more electrodes disposed toward a distal end of the percutaneous lead.

16. The method of claim 9 , wherein the pulse width is between about 30 microseconds and 35 microseconds.

17. The method of claim 9 , wherein the pulse width is between 25 microseconds and 166 microseconds.

18. The method of claim 9 wherein the frequency range is 1.5 kHz to 50 kHz.

19. The method of claim 9 wherein the frequency range is 3 kHz to 10 kHz.

20. The method of claim 9 wherein the frequency is 10 kHz.

21. The method of claim 9 wherein the portion of the electrical therapy signal is a biphasic square wave.

22. The method of claim 9 wherein the frequency range is 5 kHz to 15 kHz, the pulse width range is 30 microseconds to 35 microseconds, and the amplitude range is 0.5 mA to 10 mA.

23. A pelvic pain treatment system for treating a non-total body pain pelvic pain indication, comprising:

a spinal cord modulation system having

at least one signal delivery device configured to be implanted proximate to a target vertebral location at a patient's spinal cord, wherein the target vertebral location is between T12-L5, inclusive, and

a signal generator programmed with instructions that, when executed, treat the pelvic pain indication by generating and delivering a non-paresthesia-generating electrical therapy signal to the target vertebral location, via the at least one signal delivery device,

wherein at least a portion of the electrical therapy signal (a) is at a frequency in a frequency range of from 1.5 kHz to 100 kHz, (b) includes pulses having a pulse width in a pulse width range of 10 microseconds to 333 microseconds, and (c) is at an amplitude in an amplitude range of 0.1 mA to 20 mA.

24. The system of claim 23 , wherein the pelvic pain indication is selected from the group consisting of: osteitis pubis pain, cancer pain, gluteus maximus pain, visceral pain, piriformis pain, ischiogluteal pain, levator ani pain, and coccydynia pain.

25. The system of claim 23 , wherein the frequency range is from 3 kHz to 20 kHz.

26. The system of claim 23 , wherein the frequency range is from 5 kHz to 15 kHz.

27. The system of claim 23 , wherein the at least one signal delivery device includes a percutaneous lead having one or more electrodes disposed toward a distal end of the percutaneous lead.

28. The system of claim 23 , wherein the pulse width is between 30 microseconds and 35 microseconds.

29. The system of claim 23 , wherein the pulse width is between 25 microseconds and 166 microseconds.

30. The method of claim 23 wherein the frequency is 10 kHz.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA NAME PREVIOUSLY RECORDED AT REEL: 030656 FRAME: 0381. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 10, 2017
From: THACKER, JAMES R.; ALATARIS, KONSTANTINOS; GLINER, BRADFORD EVAN
To: NEVRO CORP.
Reel/Frame 041328/0193 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2016
From: CRG SERVICING LLC
To: NEVRO CORP.
Reel/Frame 039168/0890 →
ASSIGNMENT AGREEMENT (REAFFIRMATION) Recorded Jun 13, 2016
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: CRG SERVICING LLC,
Reel/Frame 038984/0865 →
SECURITY INTEREST Recorded Dec 12, 2014
From: NEVRO CORP.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 034619/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2013
From: THACKER, JAMES R.; ALATARIS, KONSTANTINOS; GLINER, BRADFORD EVAN
To: NEVRO CORPORATION
Reel/Frame 030656/0381 →
Continuity (4)
Continuation 13607617 · Sep 7, 2012
Provisional Application 61532523 · Sep 8, 2011
Provisional Application 61568135 · Dec 7, 2011
Related Publication 20130261696A1 · Oct 3, 2013